Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Clinical Trial Center of Third Xiangya Hospital of Central South University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Dermatitis, Atopic
Phase 1: Arthritis, Rheumatoid
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20252630 |
CTR20252630 | P1 |
Completed |
Dermatitis, Atopic |
2025-08-05 |
2025-12-06 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20231142 |
CTR20231142 | P1 |
Completed |
Arthritis, Rheumatoid |
2023-07-24 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20230780 |
CTR20230780 | P1 |
Completed |
Dermatitis, Atopic |
2023-08-10 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20220223 |
CTR20220223 | P1 |
Active, not recruiting |
Arthritis, Rheumatoid |
None |
2025-04-29 |
||
CTR20233576 |
CTR20233576 | P2 |
Completed |
Dermatitis, Atopic |
2025-03-15 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20240878 |
CTR20240878 | P2 |
Completed |
Dermatitis, Atopic |
2024-12-07 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|